Payment overview · 2025
General Payments
$1,292.58
57 reported records · 15 companies
Healthcare provider profile · identity verified
Keith M Tobin, D.O.
Allopathic & Osteopathic Physicians|Family Medicine · LIVONIA, MI · NPI 1083611560
Verified facts
What the public records show
CMS Open Payments records show Keith M Tobin, D.O. received $1,292.58 in general payments during 2025 across 57 reported records.
ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) accounted for 34.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 24 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Arexvy, Eliquis, Farxiga, Jardiance, Mounjaro, Ozempic, Rybelsus, Trelegy Ellipta.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 96 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 214 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AREXVY as an associated drug or biological on 47563 records involving 28786 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Arexvy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 78 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 214 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Mounjaro by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 58 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 347 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $449.71 | 34.8% | 21 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $319.43 | 24.7% | 15 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $107.10 | 8.3% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $95.02 | 7.3% | 4 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $62.58 | 4.8% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $49.46 | 3.8% | 2 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $42.42 | 3.3% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $34.16 | 2.6% | 2 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $26.62 | 2.1% | 1 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $26.00 | 2.0% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $18.05 | 1.4% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $16.75 | 1.3% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $15.79 | 1.2% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $15.60 | 1.2% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $13.89 | 1.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,292.58 | 57 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $449.71 | 21 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $197.57 | 8 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $107.10 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $95.02 | 4 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $89.66 | 5 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $78.18 | 4 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $49.46 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $49.46 | 2 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $42.42 | 2 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $42.42 | 2 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $32.20 | 2 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $26.62 | 1 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $26.00 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $19.68 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $19.68 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $18.05 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $16.75 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $16.75 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $15.79 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $14.48 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $13.89 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $13.89 | 1 | 2025 |
Source payment records
|
|||||
| M-M-R II Normalized: m m r ii |
Biological | Merck Sharp & Dohme LLC | $13.83 | 1 | 2025 |
Source payment records
|
|||||
| VARIVAX Normalized: varivax |
Biological | Merck Sharp & Dohme LLC | $13.83 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| AREXVY arexvy |
2025 | Arexvy | 2024 | 17 | exact normalized | Medicare Part D |
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 347 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 96 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 214 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 58 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 21 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 78 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
96 | 27 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
214 | 56 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | AREXVY open payments reported associated product |
CMS Open Payments — General Payments 47563 supporting records · 28786 recipient NPIs · example record 1190332445 |
Arexvy · 2024 Exact normalized brand match · 1 Part D row |
17 | 17 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
78 | 29 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
214 | 56 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
58 | 12 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
347 | 76 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 667 | 167 |
| Levothyroxine Sodium | Levothyroxine Sodium | 663 | 138 |
| Amlodipine Besylate | Amlodipine Besylate | 401 | 103 |
| Omeprazole | Omeprazole | 352 | 86 |
| Eliquis | Apixaban | 347 | 76 |
| Losartan Potassium | Losartan Potassium | 339 | 88 |
| Metoprolol Succinate | Metoprolol Succinate | 317 | 92 |
| Donepezil Hcl | Donepezil Hcl | 310 | 70 |
| Sertraline Hcl | Sertraline Hcl | 291 | 55 |
| Escitalopram Oxalate | Escitalopram Oxalate | 288 | 76 |
| Lisinopril | Lisinopril | 276 | 71 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 263 | 88 |
| Furosemide | Furosemide | 260 | 61 |
| Quetiapine Fumarate | Quetiapine Fumarate | 247 | 48 |
| Tamsulosin Hcl | Tamsulosin Hcl | 247 | 70 |
| Metformin Hcl | Metformin Hcl | 236 | 49 |
| Carvedilol | Carvedilol | 230 | 57 |
| Gabapentin | Gabapentin | 226 | 49 |
| Jardiance | Empagliflozin | 214 | 56 |
| Metoprolol Tartrate | Metoprolol Tartrate | 184 | 53 |
| Pantoprazole Sodium | Pantoprazole Sodium | 182 | 44 |
| Mirtazapine | Mirtazapine | 175 | 42 |
| Duloxetine Hcl | Duloxetine Hcl | 167 | 46 |
| Citalopram Hbr | Citalopram Hydrobromide | 159 | 29 |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 158 | 32 |
| Potassium Chloride | Potassium Chloride | 156 | 40 |
| Memantine Hcl | Memantine Hcl | 155 | 33 |
| Clopidogrel | Clopidogrel Bisulfate | 153 | 36 |
| Meloxicam | Meloxicam | 142 | 60 |
| Allopurinol | Allopurinol | 141 | 34 |
| Trazodone Hcl | Trazodone Hcl | 139 | 34 |
| Famotidine | Famotidine | 135 | 38 |
| Spironolactone-Hctz | Spironolact/Hydrochlorothiazid | 133 | 33 |
| Simvastatin | Simvastatin | 117 | 18 |
| Hydralazine Hcl | Hydralazine Hcl | 104 | 23 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 103 | 22 |
| Spironolactone | Spironolactone | 101 | 29 |
| Tramadol Hcl | Tramadol Hcl | 101 | 24 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 100 | 24 |
| Pravastatin Sodium | Pravastatin Sodium | 97 | 25 |
| Farxiga | Dapagliflozin Propanediol | 96 | 27 |
| Finasteride | Finasteride | 87 | 19 |
| Xarelto | Rivaroxaban | 85 | 21 |
| Divalproex Sodium | Divalproex Sodium | 81 | 11 |
| Aripiprazole | Aripiprazole | 80 | 26 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 78 | 29 |
| Levetiracetam | Levetiracetam | 75 | 14 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 73 | 27 |
| Lorazepam | Lorazepam | 71 | 20 |
| Pregabalin | Pregabalin | 65 | 18 |
| Bumetanide | Bumetanide | 64 | 16 |
| Celecoxib | Celecoxib | 64 | 25 |
| Olanzapine | Olanzapine | 59 | 14 |
| Alendronate Sodium | Alendronate Sodium | 58 | 16 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 58 | 21 |
| Ozempic | Semaglutide | 58 | 12 |
| Montelukast Sodium | Montelukast Sodium | 56 | suppressed |
| Bupropion Xl | Bupropion Hcl | 55 | 13 |
| Digoxin | Digoxin | 55 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 54 | 13 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 53 | 45 |
| Amiodarone Hcl | Amiodarone Hcl | 52 | 12 |
| Atenolol | Atenolol | 50 | 16 |
| Risperidone | Risperidone | 48 | 12 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 48 | 17 |
| Alprazolam | Alprazolam | 45 | 19 |
| Clonazepam | Clonazepam | 45 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 45 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 44 | 12 |
| Cilostazol | Cilostazol | 42 | 12 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 40 | 24 |
| Fluoxetine Hcl | Fluoxetine Hcl | 39 | 11 |
| Nifedipine Er | Nifedipine | 38 | 11 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 37 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 37 | suppressed |
| Latanoprost | Latanoprost | 36 | 15 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 36 | 14 |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 36 | suppressed |
| Ibuprofen | Ibuprofen | 34 | 11 |
| Fluticasone Propionate | Fluticasone Propionate | 32 | 15 |
| Warfarin Sodium | Warfarin Sodium | 32 | suppressed |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 31 | 12 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 31 | 28 |
| Ondansetron Hcl | Ondansetron Hcl | 31 | 21 |
| Methylprednisolone | Methylprednisolone | 30 | 24 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 30 | suppressed |
| Entresto | Sacubitril/Valsartan | 29 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 28 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 26 | 23 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 26 | suppressed |
| Fenofibrate | Fenofibrate | 26 | suppressed |
| Primidone | Primidone | 25 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 24 | 11 |
| Myrbetriq | Mirabegron | 24 | suppressed |
| Lansoprazole | Lansoprazole | 23 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 22 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 22 | 14 |
| Januvia | Sitagliptin Phosphate | 22 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 22 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 21 | suppressed |
| Glimepiride | Glimepiride | 21 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 21 | suppressed |
| Rybelsus | Semaglutide | 21 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 21 | suppressed |
| Baclofen | Baclofen | 20 | suppressed |
| Methocarbamol | Methocarbamol | 20 | suppressed |
| Ramipril | Ramipril | 20 | suppressed |
| Mesalamine | Mesalamine | 19 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 19 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 18 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 18 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 18 | 17 |
| Propranolol Hcl Er | Propranolol Hcl | 18 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 17 | 17 |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 17 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 17 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Cephalexin | Cephalexin | 16 | 12 |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 16 | suppressed |
| Fentanyl | Fentanyl | 16 | suppressed |
| Invokana | Canagliflozin | 16 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 16 | suppressed |
| Levofloxacin | Levofloxacin | 16 | 16 |
| Timolol Maleate | Timolol Maleate | 16 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 16 | suppressed |
| Valsartan | Valsartan | 16 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 15 | suppressed |
| Chlorthalidone | Chlorthalidone | 15 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 15 | suppressed |
| Glipizide Er | Glipizide | 15 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 15 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 15 | suppressed |
| Lactulose | Lactulose | 15 | suppressed |
| Mounjaro | Tirzepatide | 15 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 15 | suppressed |
| Vancomycin Hcl | Vancomycin/Water For Inj (Peg) | 15 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 15 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 15 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Calcitriol | Calcitriol | 14 | suppressed |
| Lacosamide | Lacosamide | 14 | suppressed |
| Metaxalone | Metaxalone | 14 | suppressed |
| Mirabegron Er | Mirabegron | 14 | suppressed |
| Mupirocin | Mupirocin | 14 | 11 |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 14 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 13 | suppressed |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 13 | suppressed |
| Colchicine | Colchicine | 13 | suppressed |
| Ezetimibe | Ezetimibe | 13 | suppressed |
| Fluconazole | Fluconazole | 13 | 11 |
| Oxybutynin Chloride | Oxybutynin Chloride | 13 | suppressed |
| Paliperidone Er | Paliperidone | 13 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 12 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 12 | 11 |
| Fenofibrate | Fenofibrate,micronized | 12 | suppressed |
| Hydrocortisone | Hydrocortisone | 12 | suppressed |
| Indapamide | Indapamide | 12 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 12 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 12 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 12 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 11 | suppressed |
| Brimonidine Tartrate-Timolol | Brimonidine Tartrate/Timolol | 11 | suppressed |
| Dexamethasone | Dexamethasone | 11 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 11 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 11 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 11 | suppressed |
| Loperamide | Loperamide Hcl | 11 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 11 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 11 | suppressed |
| Steglatro | Ertugliflozin Pidolate | 11 | suppressed |
| Torsemide | Torsemide | 11 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,292.58 · 57 records | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | AIRSUPRA, AREXVY, Auvelity, BREZTRI, CAPLYTA, CAPVAXIVE, ELIQUIS, FARXIGA, GARDASIL 9, GEMTESA, INGREZZA, JARDIANCE, Kerendia, M-M-R II, MOUNJARO, NURTEC ODT, Ozempic, REXULTI, Rybelsus, SHINGRIX, TRELEGY ELLIPTA, VARIVAX, VRAYLAR, ZEPBOUND | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Arexvy play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error